CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Hemovent reports the study concluded that Hemovent’s MOBYBOX ECLS device “provides excellent safety and physiologic efficacy in a 7-day (long-term) sheep experiment without visible clotting, hemolysis, or sustained reductions in fibrinogen or platelets.”

Total hip arthroplasty using a bearing combination of OXINIUM on XLPE versus traditional ceramic or metal constructs results in greatly improved survivorship and significantly reduced the need for revision. Read more.

The IMPACT study utilized the IBM Watson Truven Health Marketscan, a national commercial claims database, and analyzed data on 510 patients with lower limb amputations.

Approved by the Ministry of Health in Brazil, a group of international physicians and scientists are in the early stages of data collection utilizing Multi Radiance Medical’s handheld super pulsed laser therapy devices to improve the condition of patients.

The therapy is designed to open vessels and keep them open without the use of permanent implants in the treatment of peripheral artery disease (PAD) of the lower extremities, a painful and debilitating condition affecting over 200 million people worldwide.

OrthogenRx notes the recently published response counters this position and addresses some recently reported economic and medical benefits not acknowledged within the AAOS CPGs.

The paper, entitled “Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins”, was written by collaborators from China Medical University's Shengjing Hospital and Columbia University Medical Center in New York and demonstrates the ability of the test to detect preeclampsia at a high level of accuracy in women admitted to the hospital for any reason. The findings included over 1,500 women and were published in the peer-reviewed journal PLOS One.

The results of the study, which were selected for a podium presentation at the 40th Annual Pregnancy Meeting of the Society for Maternal-Fetal Medicine in February 2020, demonstrate that the company’s PreTRM® biomarker test can be used to predict very preterm birth, (infants born before 32 weeks of gestation) as well as increased length of neonatal hospital stay and severe adverse neonatal outcomes.

The report includes findings from a case study at Hebrew Home of Riverdale by RiverSpring Health showing that skilled nursing facilities incorporating contact-free, continuous patient monitoring can potentially aid in the early identification of acute changes in patient deterioration and rapid life-threatening treatment interventions.